Mark Bach's Insider Trades & SAST Disclosures

Mark Bach's most recent trade in Lyell Immunopharma Inc was a trade of 13,000 Option (right to buy) done . Disclosure was reported to the exchange on June 9, 2025.

Share

Note

This is a custom search result for pattern Mark Bach.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.

All Superstars

"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches "Balanced Fund" but not "Balanced Growth Fund" Balanced Fund: Use this format without quotation marks to search for all funds related to the term "Balanced Fund" The results may include "Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".

Stock	Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Lyell Immunopharma Inc	Mark Bachleda	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2025	13,000	13,000	-		-	Option (right to buy)
Structure Therapeutics Inc...	Mark Bach	CHIEF MEDICAL OFFICER	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Mar 2024	65,352	65,352	-		-	Stock Option (right to buy)
Structure Therapeutics Inc...	Mark Bach	CHIEF MEDICAL OFFICER	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Mar 2024	65,352	65,352	-		-	Stock Option (right to buy)
Structure Therapeutics Inc...	Mark Bach	CHIEF MEDICAL OFFICER	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Mar 2024	26,235	26,235	-		0	Ordinary Shares
Galera Therapeutics Inc 5-year low	Mark Bachleda	Chief Commercial Officer	Purchase of securities on an exchange or from another person at price $ 2.25 per share.	16 Mar 2023	11,000	11,000 (0%)	0%	2.2	24,717	Common Stock
Galera Therapeutics Inc 5-year low	Mark Bachleda	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Feb 2023	135,000	135,000	-		-	Stock Option (Right to Buy)
Galera Therapeutics Inc 5-year low	Mark Bachleda	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	28 Feb 2022	75,000	75,000	-		-	Stock Option (Right to Buy)
Galera Therapeutics Inc 5-year low	Mark Bachleda	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	08 Oct 2021	200,000	200,000	-		-	Stock Option (Right to Buy)

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades